DCLA
BIIB icon

Douglas C. Lane & Associates’s Biogen BIIB Stock Holding History

Douglas C. Lane & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$294K Sell
960
-212
-18% -$60.9K 0.01% 194
2015
Q3 		$342K Sell
1,172
-15
-1% -$4.95K 0.01% 190
2015
Q2 		$479K Sell
1,187
-43
-3% -$17.3K 0.01% 173
2015
Q1 		$519K Sell
1,230
-25
-2% -$9.85K 0.01% 170
2014
Q4 		$426K Buy
1,255
+15
+1% +$4.85K 0.01% 176
2014
Q3 		$410K Buy
1,240
+470
+61% +$155K 0.01% 175
2014
Q2 		$243K Buy
+770
New +$232K 0.01% 192

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Douglas C. Lane & Associates's BIIB Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Biogen (BIIB) stake by 18% in Q4 2015, selling an estimated $60.9K and leaving 960 shares worth $294K. The position accounts for 0.01% of the portfolio, ranked #194.

Douglas C. Lane & Associates first reported a position in BIIB in Q2 2014 and has held it in 7 quarters since. The position peaked at $519K in Q1 2015. 970 funds tracked by Wall St. Rank hold BIIB as of Q4 2015.

  • Douglas C. Lane & Associates held 960 shares of Biogen worth $294K as of Q4 2015.
  • Douglas C. Lane & Associates sold 212 Biogen shares in Q4 2015, an estimated $60.9K.
  • Biogen made up 0.01% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #194 holding.
  • Douglas C. Lane & Associates first reported a position in Biogen in Q2 2014 and has held it in 7 quarters since.
  • Douglas C. Lane & Associates's Biogen position peaked at $519K in Q1 2015.
  • 970 funds tracked by Wall St. Rank held Biogen as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.